Why the study?
Does a cluster-based polygenic risk score approach better stratify clinical traits and comorbidity risks in patients with Type 2 Diabetes compared to an extreme-value approach?
Population
19,734 patients with Type 2 Diabetes in an East Asian cohort
Comparison
Cluster-based strategy using K-means clustering… vs Extreme-value strategy defining high-risk groups…
Design
Cohort
Authors
Loading...
A cluster-based approach using multiple pathway-specific polygenic risk scores better stratifies Type 2 Diabetes patients by clinical traits and comorbidity risks than a simple extreme-value cutoff.
Does a cluster-based polygenic risk score approach better stratify clinical traits and comorbidity risks in patients with Type 2 Diabetes compared to an extreme-value approach?
A cluster-based approach using multiple pathway-specific polygenic risk scores better stratifies Type 2 Diabetes patients by clinical traits and comorbidity risks than a simple extreme-value cutoff.
SHEU et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: